ATGL Inhibitor

Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC₅₀ of 0.7 μM in vitro.

NG-497 is a selective human adipose triglyceride lipase (ATGL) inhibitor that targets the enzymatically active patatin-like domain of human ATGL. NG-497 has potential value for tumor research.

Hexadecyl-CoA is a non-hydrolyzable thioether analog of Palmitoyl-CoA. Hexadecyl-CoA competitively inhibits the acyl-CoA thioesterase activity of HNF-4α with a K_i of 0.3 μM, and inhibits DGAT2 activity with an IC₅₀ of approximately 2 μM. Hexadecyl-CoA also inhibits ATGL activity and serves as a reference inhibitor for DGAT2 LC/MS enzyme activity assays. Hexadecyl-CoA can be used in studies related to lipid metabolism, triglyceride synthesis and lipolysis.

Diethylumbelliferyl phosphate (DEUP) is a broad-spectrum inhibitor of serine esterase and lipases. Diethylumbelliferyl phosphate inhibits cholesteryl ester hydrolase (CEH), adipose triglyceride lipase (ATGL/cytosolic lipase), and retinyl ester hydrolase. Diethylumbelliferyl phosphate blocks the hydrolysis of triglycerides and cholesteryl esters by inhibiting key hydrolases such as CEH and ATGL, thereby inhibiting the mobilization and remodeling of lipid droplet contents, which in turn reduces intracellular reactive oxygen species (ROS) levels and inhibits apoptosis. Diethylumbelliferyl phosphate can be used in research on lipid and cholesterol metabolic diseases and Alzheimer's disease.

Atglistatin (Standard) is the analytical standard of Atglistatin. This product is intended for research and analytical applications. Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.